By Trend News Line 2024-03-19 11:30:00.
Heart & Lung Health Partners with Caristo Diagnostics for Revolutionary AI Technology
You may also like to watch : Who Is Kamala Harris? Biography - Parents - Husband - Sister - Career - Indian - Jamaican Heritage
In a groundbreaking move, Heart & Lung Health (HLH), a UK-wide network of expert cardiothoracic radiologists, has joined forces with Caristo Diagnostics to introduce the innovative CaRi-Heart® AI technology. This collaboration aims to predict patients’ risk of developing potentially fatal coronary artery disease, offering a new level of early detection and intervention.
Uncovering Hidden Risks with CaRi-Heart® Technology
Traditionally, patients experiencing chest pain would undergo a coronary computed tomography angiography (CCTA) scan to diagnose coronary artery disease. However, a significant number of these patients, despite showing no clear signs of arterial narrowing, are still at risk of heart attacks. This discrepancy often leads to missed opportunities for early intervention and prevention.
Enter CaRi-Heart® technology. Developed based on research originating at the University of Oxford, this cutting-edge AI solution can detect coronary inflammation – a crucial risk factor previously undetectable in routine CCTAs. By integrating plaque and clinical risk factors such as cholesterol levels, CaRi-Heart provides a non-invasive Fat Attenuation Index Score™ (FAI-Score™) as a patented biomarker for coronary inflammation.
You may also like to watch: Is US-NATO Prepared For A Potential Nuclear War With Russia - China And North Korea?
The Impact of CaRi-Heart® on Patient Outcomes
Recent research studies have shown that patients with no plaque and zero calcium at the time of CCTA, but abnormal CaRi-Heart test results, face significantly higher risks of cardiac mortality and major adverse cardiac events (MACEs). This highlights the importance of early detection and risk assessment in preventing potentially fatal outcomes.
Expanding Access Across the UK
With HLH now offering CaRi-Heart AI-based cardiac assessments as part of their cardiac health check package in various locations across the UK, more patients will have access to this life-saving technology. This move is set to revolutionize the way coronary artery disease is diagnosed and managed, potentially saving thousands of lives through early intervention.
The Vision of Heart & Lung Health
Dr. Jonathan Rodrigues, Chief Medical Officer & Co-Founder of Heart & Lung Health, expressed the network’s commitment to delivering world-class patient care through rapid and reliable imaging reports. With the integration of CaRi-Heart technology, HLH aims to identify patients at risk of heart attacks early on, paving the way for improved health outcomes and enhanced quality of life.
A Bright Future for Cardiovascular Health
Caristo Diagnostics, a global leader in cardiac and vascular disease diagnostics, has been at the forefront of developing AI-assisted platforms for predicting and diagnosing heart-related conditions. The partnership between Caristo and HLH marks a significant step towards transforming the landscape of cardiovascular health in the UK and beyond.
In conclusion, the collaboration between Heart & Lung Health and Caristo Diagnostics represents a major milestone in the field of cardiac diagnostics. By harnessing the power of AI technology to detect hidden risks and provide early intervention, this partnership has the potential to revolutionize the way coronary artery disease is diagnosed and managed, ultimately saving lives and improving patient outcomes..
1. Heart and Lung Health selects Caristo Diagnostics AI technology for early diagnosis of coronary artery disease UK-wide
2. Caristo Diagnostics AI technology chosen for early diagnosis of coronary artery disease by Heart and Lung Health across the UK.
